Friday, 3rd November Clinical Oncology Society of Australia Annual Scientific Meeting 2023

Antibody drug conjugates are a rapidly expanding class of treatments in oncology that fuse the specificity of a monoclonal antibody to improve the effectiveness of chemotherapy. As these develop as a new class in multiple therapy areas, those working in oncology need to understand how these modalities combine to best identify and support patients. This session will bring together experts across disease areas to cover the science, review recent data and discuss the impact on their own group of patients as well as their own experience to date. Join this interactive session to learn from other experts in the field and have your questions answered on this emerging field.

Chair:    Dr Melissa Moore

Speakers and panelists:

Dr Cath Shannon

            A/Prof Arun Azad

            Dr Sanjeev Kumar

The landscape of clinical research is constantly evolving, and the introduction of novel trial methodologies disrupt the traditional clinical trial landscape. Updates to legislation and new processes bring further change, and, while they elevate the sector, support and guidance available for the research workforce is often limited. Teletrials and Registry-based Clinical Trials are both innovative trial designs that show great promise in answering research questions in real-world populations, with particular advantages for rural and regional groups, but both have yet to have their potential fully realised, in part due to clinician apprehension and awareness. Meanwhile, the introduction of the National Clinical Trial Governance Framework (NCTGF) will significantly impact both clinical trial units and research and governance offices and their ability to capture and report metrics. Finally, researchers stepping into business management roles were found to lack available fit-for-purpose and tailored support. Newly released education, including toolkits, online courses and live resources have been developed to assist the research workforce in these areas, delivered as part of a broader overview of context with practical take away lessons in these areas.

Speakers:

• Prof Peter Gibbs, Division and Laboratory Head, Walter and Eliza Hall Institute of Medical Research
• Marian Lieschke, Manager, Parkville Cancer Clinical Trial Unit
• Narelle McPhee; Cancer Research Manager, Bendigo Cancer Centre
• Michelle Barrett, Head of Education, VCCC Alliance
• Duncan Colyer - Senior Manager, Clinical Research, VCCC Alliance
• Eleonora Kay - Clinical Trial Innovations, VCCC Alliance
• Jessica Freeman - Regional Project Manager, VCCC Alliance

Until recently, standard of care treatment options for advanced endometrial carcinoma (EC) have been limited to cytotoxic treatment regimens. This session aims to provide an overview of the current EC clinical trial landscape and will delve into a real-world clinical case study of patient management with the recent PBS reimbursed combination of Lenvatinib and Pembrolizumab.

Agenda:

• Endometrial cancer clinical trial landscape

• Case presentation: exploring a novel treatment approach in the management of endometrial cancer

Lenvima® (lenvatinib) PBS Information: Authority required (STREAMLINED). Lenvima in combination with Keytruda (pembrolizumab) is PBS listed for certain patients with advanced, metastatic or recurrent endometrial carcinoma. Refer to PBS Schedule for full authority information.

Please review full Lenvima Product Information before prescribing, available from www.eisai.com.au/PI

Please review full Keytruda Product Information before prescribing, available from www.msdinfo.com.au/keytrudapi

Panellists:

• Dr Michelle Wilson - Medical oncologist and Service Clinical Director Cancer and Blood Research, Auckland City Hospital, New Zealand

• Associate Professor Tarek Meniawy - Medical Oncologist, Sir Charles Gairdner Hospital & Linear Clinical Research, Clinical Associate Professor, University of Western Australia

• Financial toxicity: An unacceptable side effect of cancer in Australia - Megan Varlow
• Tackling financial toxicity, the views of health professionals - Louisa Gordon
• Challenges and solutions to cancer-related financial toxicity according to Australian health professionals: qualitative results from a national survey - Jordana McLoone
• A National Roadmap to Addressing Financial Toxicity - Raymond J Chan

• Global Green and Healthy Hospitals OR Roadmap for healthcare decarbonisation  - Stefanie Carino
• Driving systems change for sustainable healthcare: buy-in from the ground up  - Angie Bone
• Clinical leadership to reduce the environmental impact of health care. - Forbes McGain
• Decarbonising paediatric cancer care: case-study from the Kids Cancer Centre  - Felicity Wright

10:00 AM Panel discussion

• The current and future role of parp inhibitors in ovarian cancer  - Michelle Wilson
• What’s new in medical oncology treatments for endometrial cancer? - George Au-Yeung
• What’s new in surgical therapies for gynae cancers? - Simon Hyde
• Is there a role for ctDNA in the management of gynae cancers? - Rachel Delahunty

12:20 PM Panel discussion

• Finding the new normal - Jodie Lydeker
• Managing pain and related symptoms in cancer survivors. - Paul Glare
• Cancer fatigue - Tackling a hidden, disabling symptom in routine cancer care - Elizabeth J Pearson
• Scalable Interventions for Sleep after Cancer - Joshua Wiley

12:00 PM Panel discussion

• Consumer Partnership Impacting Australian Health Technology Assessment Policy - Karen Trapani
• Treatment Patterns in Victoria Across Three Cancers: An In-Depth Analysis - Fanny Franchini
• Examining factors affecting cancer treatment costs - Ou Yang
• Uptake of recently PBS-listed cancer medicines - Benjamin Daniels
• Forecasting the future impact of novel therapies on cancer treatment in Australia - Fanny Franchini

• The Axilla – decreasing surgery, decreasing lymphoedema - David Speakman
• Decreasing breast radiotherapy - Fiona Hegi-Johnson
• Partial breast reconstruction - Satomi Koide
• Less travel, more options – breast surgery in regional Victoria. - Joshua Lin

• Challenges and successes of implementing the distance-delivered ‘Engage’ survivorship program for childhood cancer survivors in clinical practice - Christina Signorelli
• Scaling Up and Out with Finding My Way! - Lisa Beatty
• The strategies employed to recruit for MindOnLine - a 9 week online mindfulness program for people who have completed treatment for bowel, breast or prostate cancer - Natalie Winter
• Online peer support for young cancer survivors, and their parents, in community settings: Learnings from the Recapture Life and Cascade implementation trials - Ursula M Sansom-Daly
• Redkite and the Behavioural Sciences Unit, Kids Cancer Centre: The power of partnership to create national impact for children with cancer and their families - Eden G Robertson

Chairs: Jeff Dunn and Grant McArthur

• Exploring the evidence for immunotherapy in Breast Cancer - Sherene Loi
• Access to Oncology Medicines (ATOM) - Cary Adams
• Survivorship-Reconsidering Clinical Care, Policy, and Research Priorities for the Modern Era - Michael Jefford

Panel discussion including Dr Donna Milne

Presenter: Prof Bogda Koczwara AM